Prevention and suppression of experimental allergic encephalomyelitis by an orally active leukocyte recruitment inhibitor, NPC 16570.

Abstract

An orally active leukocyte recruitment inhibitor, NPC 16570 (N-[9H-fluoren-9-ylethoxycarbonyl]-4-aminobenzoic acid), was evaluated in experimental allergic encephalomyelitis (EAE) in rats. The mean time of disease onset in control animals was 12 +/- 1 days, with peak average clinical scores of 2.5 +/- 0.2, accompanied by perivascular infiltration of inflammatory cells into the CNS. Daily administration (p.o.) of NPC 16570 reduced the clinical severity (by 70%) at 10 and 30 mg/kg, and at 100 mg/kg, no clinical symptoms were detected. When NPC 16570 (100 mg/kg) treatment was initiated 7 days after EAE induction, the severity (75% inhibition) and duration of the disease were attenuated; 2 out of 6 animals showed no overt clinical symptoms and perivascular cell infiltration was prevented, suggesting potential utility in autoimmune diseases.

• Authors: V C Lowe, L Noronha-Blob
• Journal: Agents and actions (Agents Actions) Vol. 39 Spec No Pg. C83-5 ( 1993) ISSN: 0065-4299 [Print] Switzerland
• PMID: 8273595 (Publication Type: Journal Article)

Chemical References

• Aminobenzoates
• Anti-Inflammatory Agents, Non-Steroidal
• Fluorenes
• N-(9H-fluoren-9-ylethoxycarbonyl)-4-aminobenzoic acid

Topics

• Administration, Oral
• Aminobenzoates (administration & dosage, therapeutic use)
• Animals
• Anti-Inflammatory Agents, Non-Steroidal (administration & dosage, therapeutic use)
• Encephalomyelitis, Autoimmune, Experimental (drug therapy, pathology, prevention & control)
• Fluorenes (administration & dosage, therapeutic use)
• Guinea Pigs
• Male
• Rats
• Spinal Cord (drug effects, pathology)